AMSTERDAM, May 31, 2018 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a
global leader in health technology, will showcase a broad range of
integrated oncology solutions, including IntelliSpace Genomics and
IntelliSpace Oncology, to help support and scale precision medicine
programs to assist oncologists with treatment decisions at the 2018
American Society of Clinical Oncology Annual Meeting (ASCO) in
Chicago, Ill.
Individualized, precision medicine is key in reaching accurate
diagnoses and effective treatment plans for cancer patients, but
should be informed through accepted best practices to maximize
quality of care and outcomes. These patients require constant
vigilance and collaboration across multiple domains, and
oncologists can face challenges when trying to compile a complete
picture of all necessary patient information to support the
decision making process. With new technologies and solutions like
IntelliSpace Oncology, a cloud-based platform integrating
information across different clinical domains such as radiology,
pathology, EHR systems and genomics, all key patient data is
seamlessly incorporated into one location, to provide a clear,
intuitive view of patient status in its disease and state context
that facilitates data-driven clinical decision support.
"Philips is committed to empowering clinicians with successful
oncology care pathways by providing them with the necessary
solutions to do so," said Louis
Culot, general manager, Oncology Informatics, Philips. "As a
leader in oncology diagnostics, informatics and therapy, Philips is
always striving to find ways to make life better for those
suffering from cancer, as well as those responsible for delivering
that care."
Continued partnerships with industry leaders on precision
medicine
Philips is dedicated to addressing healthcare's quadruple aim of
better clinical outcomes, lower costs and improved patient and
staff satisfaction through connected care technologies and
partnerships with industry leaders. To that end, during ASCO17,
Philips announced that it teamed up with NAVICAN, an Intermountain
Healthcare Company, to accelerate the delivery of precision
medicine to health systems worldwide. In the Philips Booth (#7159)
at ASCO 2018, NAVICAN will demonstrate its TheraMap™ offering, a
comprehensive end-to-end solution for precision medicine integrated
at the point-of-care. In addition to NGS test results, NAVICAN's
TheraMap report includes expert therapy recommendations prioritized
by medical oncologists and access to experienced nurse navigators
to help patients and their caregivers get the precision therapy
they need as soon as possible. In a previously published study,
NAVICAN's approach demonstrated doubling of progression-free and
overall survival, as well as an average 21% reduction in weekly
healthcare costs [1].
Covering detection through treatment decision and
surveillance
At ASCO18, Philips will spotlight specific, end-to-end oncology
solutions to empower data-driven clinical decision support driving
clinical, operational and financial benefits across the following
key areas:
Integrative Diagnostics:
- IntelliSpace Genomics, a cloud-based precision medicine
platform, automates genomic analysis for more precise diagnostics
to inform therapy options and clinical trials. The solution also
provides automated end-to-end workflows and customizable
knowledgebase and report generation, while also improving data
safety and security.
- IntelliSpace Portal, an advanced visualization tool,
supports the clinical workflow across the cancer care continuum,
including the ability to assess lung nodules over time with the CT
Lung Nodule Assessment, monitor tumor progression and treatment
response with Multimodality Tumor Tracking, and prepare for complex
oncology procedures with 3D modeling.
- IntelliSite Pathology, the first and currently only
digital pathology solution in the U.S. to be marketed for primary
diagnostic use, can aid pathologists to view and diagnose digital
images of surgical pathology slides to streamline workflow and
extend collaboration with the aim of increasing diagnostic
confidence.
Deeper Insights:
- IntelliSpace Oncology assists with complex treatment
decisions, including hundreds of FDA-approved anti-cancer agents,
and provides daily patient care insights based on evidence-based
decision tools to promote guidelines adherence.
- OncoSignal, a proprietary test system unique to Philips,
measures signaling pathway activity in individual tumor samples to
predict targeted therapy response. Test results could help to
select the best systemic treatment, allowing for simplified
testing, better stratification and new therapy options [2].
Confident path:
- The Dana-Farber Clinical Pathways will be deployed
through the Philips IntelliSpace Oncology Platform, providing
clinical decision support to physicians via a patient-centric
solution. The implementation will help oncologists quickly reach
the most appropriate cancer treatments for patients, based on the
unified view of the patient across diagnostic modalities and the
embedded knowledge of Clinical Pathways, and can be delivered
through existing EHR platforms.
- To drive efficient and personalized patient specific
radiotherapy treatment planning workflows, Philips has integrated
Sun Nuclear's PlanIQ technology into Pinnacle to create Pinnacle
Auto-Planning with PlanIQ. This allows for better management of
risk with automated, template driven planning workflows that can
also assist in MACRA and ACR accreditation initiatives and drive
continuous quality improvement with benchmarking tools.
- TissueMark, uses deep learning AI technology to
accurately identify tumor samples and estimate tumor percentages.
This empowers pathologists and labs to enhance the quality of
macrodissection and ultimately aids in reducing costs in molecular
testing caused by insufficient tumor input [3].
During ASCO 2017, Philips announced it had signed an agreement
with Memorial Sloan Kettering Cancer center to develop new
methodologies and informatics approaches for advanced precision
diagnostics to help uncover the drivers for cancer at the
single-cell level. In 2018, Philips has signed additional
agreements with Dana-Farber and Perlmutter Cancer Center at NYU
Langone Health.
For more information on the full portfolio of Philips integrated
oncology solutions and Philips' presence at the American Society of
Clinical Oncology Annual Meeting, visit Booth #7159 on the exhibit
floor, and follow @PhilipsLiveFrom for #ASCO18 updates throughout
the event.
References
[1] Haslem, D S, Chakravarthy I, et al. "Precision Oncology in
Advanced Cancer Patients Improves Overall Survival with Lower
Weekly Healthcare Costs." Advances in Pediatrics., U.S.
National Library of Medicine, 2 Feb.
2018.
[2] OncoSignal is available for Research Use Only and not for use
in Diagnostic Procedures (not for use in clinical settings).
[3] TissueMark is not intended for diagnostic, monitoring or
therapeutic purpose or in any other manner for regular medical
practice.
For further information, please contact:
Kathy O'Reilly
Philips Group Press Office
Tel: +1 978-221-8919
E-mail: Kathy.Oreilly@Philips.com
Twitter: @kathyoreilly
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2017 sales of
EUR 17.8 billion and employs
approximately 74,000 employees with sales and services in more than
100 countries. News about Philips can be found
at www.philips.com/newscenter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/philips-showcases-end-to-end-oncology-informatics-solutions-at-asco-2018-300657368.html
SOURCE Royal Philips